Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Denavir OTC Switch Falters On Viral Resistance Questions

Executive Summary

Two FDA advisory committees unanimously disagreed on whether to recommend approval of the Rx-to-OTC switch of SmithKline Beecham's Denavir 1% penciclovir cream for cold sores on Dec. 1.

You may also be interested in...



GSK Valtrex Cold Sore Promotions Will Focus On One-Day, Oral Treatment

GlaxoSmithKline's Valtrex herpes labialis promotions will focus on the drug's convenience as an oral, one-day therapy following FDA's supplemental approval of the antiviral

GSK Valtrex Cold Sore Promotions Will Focus On One-Day, Oral Treatment

GlaxoSmithKline's Valtrex herpes labialis promotions will focus on the drug's convenience as an oral, one-day therapy following FDA's supplemental approval of the antiviral

SmithKline Denavir $10 Mil. DTC Television, Print Campaign Debuts July 12

SmithKline Beecham's Denavir (penciclovir) $10 mil. direct-to-consumer campaign will debut July 12.

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel